Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance

Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance

COTI-2 is currently being evaluated in a phase I clinical trial for the treatment of gynecological and other solid cancers. As a thiosemicarbazone, this compound contains an N,N,S-chelating moiety and is, therefore, expected to bind endogenous metal ions. However, besides zinc, the metal interaction...

Full description

Bibliographic Details
Main Authors: Vivien Pósa, Alessia Stefanelli, Julia H. Bormio Nunes, Sonja Hager, Marlene Mathuber, Nóra V. May, Walter Berger, Bernhard K. Keppler, Christian R. Kowol, Éva A. Enyedy, Petra Heffeter
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cancers
Subjects:
thiosemicarbazones
COTI-2
zinc
copper
iron
metal binding
Online Access:https://www.mdpi.com/2072-6694/14/18/4455

Internet

https://www.mdpi.com/2072-6694/14/18/4455

Similar Items